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ABSTRACT 
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In this study, we explore the effects of NURF depletion on the growth of tumors in immune-
competent mice. NURF depletion in tumors results in reduced tumor growth in immune-
competent mice, suggesting enhanced anti-tumor immunity. Analysis of the tumor 
microenvironment by flow cytometry revealed a significantly elevated CD8 and progressively 
elevated activated CD8 phenotype in Bptf KD tumors, possibly contributing to the increase in 
cell death and decrease in tumor weight observed. Examination of antigen presentation was 
evaluated using the OT-1 and Pmel-17 models, though no significant difference in cytotoxicity 
was observed as measured by LDH and/or IFNγ assays. This indicates possible novel antigen 
presentation mechanisms in tumor cells, and not increased presentation of existing antigens, 
contributes to the decreased tumor weight observed in Bptf KD tumors.
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INTRODUCTION 
Cancer affects millions of people worldwide each year. Even considering the great 
advances made in the past 25 years, resulting in a 10-18% decrease in death rate, 1 in 4 deaths in 
the United States continues to be attributed to cancer [1].  With these statistics looming over us, 
it’s no surprise that the research community has been focused on not only what causes cancer, 
but how to overcome or even cure cancer for future generations. Immunotherapies, a relatively 
new concept focusing on the ability to manipulate and take advantage of our body’s existing 
defense mechanisms, have gained notoriety with their ability to mitigate diseases that previously 
had a grim outlook and little to no available therapy. Today’s immunotherapies include both 
passive and active immunotherapies, with passive therapies encompassing tumor-targeting 
monoclonal antibodies (mAbs), adoptive cell transfer (ACT), and oncolytic viruses, and active 
immunotherapies including many anticancer vaccines, dendritic cell based therapies, 
immunomodulatory mAbs, and introduction of immune-stimulating cytokines [2,3,4,5,6]. 
Although current immunotherapies have made great strides in modern medicine and research, 
there are still many avenues yet to be exploited. One area of research harboring potential 
therapeutics is epigenetics and its included chromatin remodelers. 
Epigenetics 
Deoxyribonucleic acid (DNA), the hereditary material of life, is present in the nucleus of 
every cell; with a single cell being only 5-6µm in diameter on average, a significant amount of 
compaction must occur to fit approximately 6 feet of DNA into the nucleus [7]. In order to 
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complete this compaction, DNA goes through a series of folding to create a complex structure 
called chromatin (Figure 1). At its fundamental level, approximately 150 base pairs (bp) of DNA 
then wrap around a histone octamer core 1.7 times, forming a nucleosome [7,8]. Nucleosomes 
continue to fold tightly on themselves, creating a chromatin fiber, which can further fold into a 
chromosome that is visible during metaphase.  
 
Figure 1: Compaction of DNA Inside the Nucleus. DNA is compacted into chromatin, the 
basic unit of which is the nucleosome. [9] 
 
While chromatin provides a means for DNA to fit inside the nucleus, it also presents a 
problem; approximately 80 percent of DNA is wrapped around nucleosomes, and the segments 
of DNA wrapped around these histone octamers are generally inaccessible to transcription 
factors which are required for gene expression [10]. Epigenetics solves this problem with the 
introduction of histone variants and reversible modifications on histones including methylation, 
acetylation, and phosphorylation. These histone modifications are then recognized in part by 
chromatin remodeling complexes. In one example, the SWI/SNF family of chromatin 
remodeling complexes slides the nucleosome 10 bp in either direction in an adenosine 
triphosphate (ATP)-dependent manner, thereby exposing previously inaccessible sites [11,12]. 
 Exposure of inaccessible sites allows transcription factor binding which can in turn 
transcription. 
 
NURF 
Nucleosome Remodeling Factor (NURF), a member of
remodeling complexes, slides the nucleosome in 
stable position of DNA sequence
tail of histone H4 must be present, as well a
three distinct subunits; the Bromodomain PHD
largest subunit, the ATPase SNF2L, and
aspartic acid (WD) repeat combine to create the human form of NURF
Figure 2: The NURF Complex 
Bptf, SNF2L, and pRABP46/48 subunits. [
 
Previous work has shown
candidate to manipulate for studies of 
embryogenesis as well as thymocyte maturation, and has been shown to be embryonic lethal, but 
is not cell essential [15,16]. These 
illustrating its potential as a therapeutic agent
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 the ISWI family of 
10 bp increments onto a thermodynamically 
 [11,12,13]. For nucleosome remodeling by NURF to occur, the 
s its N-terminal residues [14]. NURF consists of 
-finger containing transcription factor (Bptf), the 
 the pRBAP46/48 subunit containing a tryptophan
 (Figure 2)
 
in Humans. The NURF complex in humans consists of the 
8] 
 the subunit Bptf to be unique to NURF, making 
this chromatin remodeler [8]. Bptf plays a role in mouse 
characteristics highlight the importance of Bptf while
 against cancer.  
regulate 
chromatin 
-
 [8].  
it the preferred 
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NURF in Cancer 
The gene encoding the Bptf subunit of NURF is located on the long arm of chromosome 
17 [2]. Previous studies have demonstrated this arm of chromosome 17 is duplicated frequently 
in primary human cancers including breast, brain, liver, and lung cancers, implicating Bptf may 
play a role in tumorigenesis [17,18,19,20]. One study has identified a non-reciprocal 
translocation (der(X)t(X;17)) in lung cells maintained in continuous culture  that occurs within 
the Bptf gene, and further showed elevated Bptf messenger ribonucleic acid (mRNA) levels and 
increased cell proliferation in cells containing this translocation [21]. 
 
 
Tumorigenesis 
Tumorigenesis occurs when cells that functioned normally no longer respond to growth 
and differentiation control mechanisms. Tumors begin when a single cell obtains a sustainable 
genetic mutation that increases its ability proliferate when it would typically be eliminated [22]. 
This hyperplastic cell continues to proliferate, creating a population of cells with similar genetic 
makeup. At some point, possibly years later, one of these hyperplastic cells can acquire an 
additional genetic mutation, resulting in further abnormal growth and appearance, and the 
establishment of cancerous cells [22,23]. These cancerous cells may continue to acquire 
mutations that will allow them to become invasive and likely metastatic.  
Accumulation of mutations in cancer cells provides them with the characteristics required 
to evade established proliferation control mechanisms. These characteristics include self-
sufficiency for growth signals, insensitivity to anti-proliferative signals, and evasion of 
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apoptosis, among others [24]. One mechanism for the continued growth of cancer cells is 
avoidance of detection and destruction by the immune system [25, 26, 27]. 
 
Role of the Immune System 
A major player in the recognition of harmful cells within an organism is the body’s 
immune system. The adaptive immune system comes into play when the body’s innate, or 
immediate, immune system is overwhelmed and cannot fully eliminate its intended target [28]. 
The adaptive immune system consists of a variety of specialized cells that sample the 
surrounding environment and present the information to effector cells capable of responding 
appropriately [29].  
Antigen presenting cells (APCs) such as macrophages and dendritic cells, members of the 
innate immune system, sample the environment by endocytosis [30].  Information taken in is 
then processed and presented on the surface of the cell as a peptide in complex with a Major 
Histocompatibility Complex (MHC) molecule. APCs then travel to a peripheral lymphoid organ, 
such as a lymph node, where they interact with and activate effector T cells recognizing the 
specific antigen presented [31].  
The effector cells of the adaptive immune system include cluster of differentiation marker 
(CD) 4 and CD8 T cells. CD4 and CD8 T cells become activated when their surface T-cell 
receptor (TCR) interacts with the peptide:MHC complex on the APC [32]. While CD4 cells, also 
known as helper T cells, assist in the activation or production of other immune cells to eliminate 
pathogens, CD8 cells or cytotoxic T lymphocytes have both direct and indirect cytotoxicity 
mechanisms.  
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CD8 cells eliminate pathogens and infected cells by inducing apoptosis. Induction of 
apoptosis is achieved through a variety of mechanisms including induction of the Fas/TRAIL 
pathway [32], release of cytotoxic granules including perforin and granzyme [32], or cytokines 
such as interferon (IFN)-γ [33]. While cytotoxic granule release induces apoptosis by forming 
holes in target cell membranes and activating caspases in the target cell that eventually act to 
degrade target cell DNA [28,33], IFN-γ acts by increasing MHC Class I molecule levels on the 
target cell surface [34]. Increase of MHC Class I levels increases the likelihood a target cell will 
be recognized and apoptosis induced. IFN-γ also activates APCs and recruits them to the site of 
interest [28]. 
The activation of effector T cells depends on the recognition of a specific antigen by the 
TCR, as previously mentioned. This antigen is presented to the TCR by the peptide:MHC 
complex on the APC’s cell surface [31]. In addition to their effector functions, CD4 and CD8 
cells differ in the class of MHC molecule they recognize, with CD4 cells recognizing antigen 
presented by MHC Class II molecules and CD8 cells recognizing antigen presented by MHC 
Class I molecules [28]. NURF has been shown to preferentially regulate nucleosome occupancy 
across the MHC locus over other sites in the genome, implying it may have a role in regulating 
gene expression at the MHC, thereby regulating its activity (Figure 3A) [35]. Consistent with this 
model were observed significant changes in genes around MHC in multiple cells including 
embryonic stem cells (ESCs), mouse embryonic fibroblasts (MEFs), and double positive (DP) 
thymocytes with knock-out (KO) of Bptf (Figure 3B).   
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Figure 3: NURF Regulation of the MHC Locus and Associated Genes. (A) NURF 
preferentially regulates nucleosome occupancy across the MHC as compared to other loci in 
multiple cell types including embryonic stem cells (ESC), double positive thymocytes (DP), and 
mouse embryonic fibroblasts (MEF). (B) Microarray data from MEF, DP thymocyte, and ESC 
Bptf KDs show dysregulation of genes involved in tumorigenesis and antigen processing. 
Antigen processing genes shown include the TAP genes located within MHC genes at the MHC 
locus. 
 
MHC Class I Peptide Presentation 
Presentation of peptides on the cell surface of APCs via MHC molecules is regulated by a 
complex known as the proteasome in conjunction with the transporter associated with antigen 
process (TAP) complex [36]. The proteasome is responsible for degrading proteins into peptide 
fragments that are then transported from the cytosol into the endoplasmic reticulum (ER) via the 
TAP complex [37,38]. MHC Class I molecules preferentially present peptides of 8 to 11 amino 
acids in length [39]. When the proteolytic subunits of the proteasome core are replaced by the 
LMP2 and LMP7 catalytic subunits, the immunoproteasome is formed [40,41]. 
Immunoproteasome formation is induced by interferons and leads to a different cleavage pattern 
preference [40,41,42].  This differential cleavage pattern results in increased generation of 
peptides with a hydrophobic base and basic COOH termini – peptide fragments that are favored 
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by the TAP complex for uptake into the ER and have optimal binding to MHC Class I molecules 
(Figure 4) [40,41,43].  
 
Figure 4: MHC Class I Antigen Processing. Proteins are broken down into peptide fragments 
in the cytosol (gray) by the proteasome. Peptide fragments are transported into the endoplasmic 
reticulum (white) by the TAP complex (green) for presentation on MHC Class I molecules 
(yellow) [28]. 
 
Previous Work in the Landry Lab 
To begin investigating the role of Bptf in cancer, the Landry Lab injected cancer cell 
lines with control or Bptf shRNA retrovirus introduced knock down (KD) into the fourth 
mammary fat pad or flank of the respective syngeneic mouse strain. The two separate cancer cell 
lines and their derived tumors used were 4T1 and B16F10. The first cell line, 4T1, is an animal 
model for stage IV human breast cancer [44]. 4T1 cells grow in BALB/c mice and generate 
extremely tumorigenic and invasive tumors that can spontaneously metastasize from the site of 
the primary tumor to a variety of distant sites including lymph nodes, liver, lung, and brain [45]. 
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Because of its metastatic characteristics, as well as the ability to remove the primary tumor 
surgically [46], 4T1 cells provide a reasonable mouse model for studying human breast cancer 
and has such become well characterized and frequently used in cancer research [47, 48, 49]. 
Another cancer cell line used was B16F10. B16F10 cells grow in C57BL/6 mice and are a well-
established and frequently used mouse model for melanoma [50] and, similar to 4T1, are capable 
of spontaneously metastasizing to sites such as lymph nodes, lung, and brain [51, 52]. 
Previous work in the lab involving the injection of 4T1 Bptf KD and control cell lines 
into the fourth mammary fat pad of BALB/c mice which resulted in a significant decrease in the 
weight of Bptf KD tumors compared to tumors derived from control cell lines (Figure 5A). 
However, when injected into immune compromised NSG mice, a return to control phenotype of 
the tumors was observed, implicating the immune system as a major contributor to the decreased 
weight of Bptf KD tumors (Figure 5B). Similar studies using the B16F10 tumor model show 
reduced tumor sizes when Bptf KD cells are introduced into the flank of immune competent 
C57BL/6 mice (Figure 5C). 
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Figure 5: Weights of Bptf KD Tumors Decreased in BALB/c and C57BL/6 but not NSG 
Mice. (A) 4T1 Bptf KD cell lines injected into the fourth mammary fat pad of immune 
competent BALB/c mice created tumors of significantly decreased weight as compared to 
controls. (B) Reappearance of control phenotype in Bptf KD tumors when 4T1 cell lines were 
injected into immune deficient NSG mice. (C) B16F10 Bptf KD cell lines injected into the flank 
of immune competent C57BL/6 mice were significantly decreased in weight as compared to 
controls. 
 
In addition to the return to control phenotype observed in immune compromised mice, 
previous data demonstrating that NURF preferentially occupies the MHC locus strongly 
implicated the immune system playing a critical role in the molecular mechanism behind the 
observed decreased weight of Bptf KD tumors [35]. The MHC locus is also known to include 
TAP and LMP genes [43]. Armed with all of this information, microarray data was collected to 
determine what genes may be dysregulated in Bptf KD cells. Results from these experiments 
illustrated dysregulation of a variety of genes, most interesting of which were upregulation of the 
TAP and LMP genes.  
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Figure 6: Similar MHC Class I Expression in Bptf Control and KD Cells. (A) qPCR analysis 
of the MHC Class I genes H2D1, H2K1, and B2m in 4T1 showing no significant difference 
between control and Bptf KD lines. (B) qPCR analysis in B16F10 showing no significant 
difference between control and Bptf KD lines. (C,D) Flow cytometry analysis of MHC Class I 
expression molecules including H2-A, H2-D, and H2-K in both 4T1 and B16F10 lines. 
Upregulation of H2-K is seen in 4T1, and upregulation of both H2-K and H2-D are seen in 
B16F10. Isotype is shown in gray, control in black, and two separate Bptf KD lines shown in 
blue and red.  
 
 
With TAPs and LMPs play a role in MHC Class I antigen processing, studies were 
conducted to determine if these upregulated genes correlated with an increase in MHC Class I 
expression on the cell surface. Flow cytometry analysis of protein levels showed an increase H2-
K in 4T1, and an increase in both H2-K and H2-D in B16F10 (Figure 6). These results were 
inconsistent with mRNA levels measured using qPCR. Data obtained through qPCR revealed 
that none of the MHC Class I genes in mice, including H2-K, H2-D, and β2-microglobulin 
(B2M), had significantly different expression levels in Bptf KD cell lines when compared to 
controls (Figure 6).  
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Microarray data was also confirmed by quantitative polymerase chain reaction (qPCR), 
showing an upregulation of TAP1, TAP2, LMP2, and LMP7 in 4T1 and B16F10 cell lines with 
Bptf KD as compared to controls (Figure 7).   
  
Figure 7: Upregulation of MHC Class I Antigen Processing Associated Genes. (A) qPCR 
analysis of antigen processing genes associated with MHC Class I antigen presentation showing 
a significant increase in expression of the Lmp2, Lmp7, Tap2, and Tap2 genes in 4T1 Bptf KD 
cells as compared to control. (B) Similar qPCR performed on B16F10 cells showing a significant 
increase in expression of Lmp2, Lmp7, Tap1, and Tap2 in Bptf KD as compared to control. 
 
Data was collected showing the importance of CD8 T cells in obtaining the phenotypic 
difference between Bptf KD and control tumors. Through systematic depletion of CD4, CD8, 
and natural killer (NK) cells using antibodies against each of the cell types, it was revealed that 
CD4 and CD8 cells are required in the mechanisms at play in Bptf KD cells. This is illustrated in 
Figure 8, which shows a reappearance of control phenotype in Bptf KD tumors when mice were 
depleted of either CD4 or CD8 T cells. 
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Figure 8: Systematic Depletion of CD4 and CD8 Cells Diminishes Reduced Growth of Bptf 
KD Tumors. (A,B) Systematic depletion of CD4, CD8, and NK cells using monoclonal 
antibodies against each, showing reappearance of control phenotype in Bptf KD lines when CD4 
or CD8 T cells are depleted in both 4T1 and B16F10. 
 
Lactate dehydrogenase (LDH) and IFN-γ cytotoxicity assays also provided evidence 
suggesting that CD8 T cells are important in Bptf KD tumor regression. To measure cell death 
by LDH cytotoxicity assay, supernatants from cultures containing target (tumor) cells in the 
presence of effector (CD8+ T cells) are obtained. LDH is a stable cytosolic enzyme that is 
released from cells upon cell lysis [61] into the culture supernatant. When placed in the presence 
of tetrazolium salt, the NADH released via LDH is oxidized, and a red formazan product is 
formed. Presence of red formazan product as detected by absorbance at 490nm is proportional to 
the number of cells lysed.  
14 
 
When released by activated CD8 T cells, IFN-γ is able to bind to its receptor and activate 
downstream pathways such as the JAK-STAT pathway and further induce apoptosis [62]. An 
ELISA assay specific for mouse IFN-γ was performed using culture supernatants from control 
and Bptf KD cells in the presence of CD8 T cells. To detect IFN-γ presence, cells are placed in 
primary capture antibody, a following secondary detection antibody, placed in the presence of 
Avidin-horseradish peroxidase (HRP), and finally combined with tetramethylbenzidine (TMB) 
substrate solution. The addition of Avidin-HRP produces hydrogen peroxide which, in the 
presence of TMB, oxidizes TMB and creates a soluble blue reaction product, turning the reaction 
solution from red to blue [63]. Analysis of the presence of blue reaction product is detected by 
absorbance at 450 nm and is proportional to the presence of IFN-γ released by CD8 T cells. 
Results from these assays demonstrated that CD8 T cells obtained from the spleen of a 
BALB/c (for 4T1) mouse and primed on Bptf KD targets are able to kill Bptf KD tumor cells 
more effectively than CD8 cells primed on control targets are able to kill control tumor cells 
(Figure 9). 
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Figure 9: CD8+ T Cells Show Enhanced Killing of Bptf KD Tumor Cells. (A) LDH and  
(B) IFN-γ cytotoxicity assays reveal CD8+ T cells kill Bptf KD cells (shRNA 1 and 2) more 
efficiently than control cells. Ratios shown (5.1, 10.1, 20.1) represent the effector to target ratios 
utilized.   
 
This data illustrates the likelihood of antigen presentation as well as CD8 cells playing 
critical roles in the difference in tumor regression between Bptf KD and control tumors. 
Hypothesis/Aims of the Study 
We have shown through antibody depletion and cytotoxicity assays, that CD8 T cells are 
crucial for Bptf KD tumor regression, however little is known about the CD8 T cell population 
phenotype in vivo. Our first aim is to determine if Bptf KD tumors showed differential 
recruitment or activation of CD8 T cells in comparison to control tumor cells. We 
hypothesize that Bptf KD tumors will show a more activated CD8 T cell population when 
compared to control tumor cells. 
16 
 
It has previously been shown that Bptf preferentially occupies the MHC locus. 
Microarray and qPCR data have also revealed that Bptf upregulates genes involved in antigen 
processing and presentation for MHC Class I molecules (i.e. TAPs and LMPs). It is, however, 
unknown whether Bptf KD tumor cells present antigen on their cell surface with greater 
efficiency or if they instead present novel antigens to CD8 T cells. In our second aim, we 
hypothesize that Bptf KD tumor cells will show similar antigen presentation as controls, 
indicating novel antigen presentation is the likely mechanism for the observed Bptf KD 
tumor phenotype.  
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MATERIALS AND METHODS 
 
Cell Culture and Maintenance 
Mouse breast cancer (4T1 from Fred Miller, Wayne State University) and melanoma 
(B16F10 from ATCC) cell lines were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS), 1X non-essential amino 
acids (NEAA), 2mM glutamine, and 100 units/mL penicillin and 100 µg/mL streptomycin at 
37.0° Celsius (C )and 5.0% CO2. Media was changed every 2-3 days.  
 
Creating Bptf KD Cell Lines 
Mouse breast cancer (4T1) and melanoma (B16F10) cell lines were plated on 6-well 
plates and, upon reaching 30-50% confluence, transduced with retroviral shRNA (pSIREN 
Retro-Q, Clontech) targeting Bptf and containing puromycin resistance. Cells were incubated 
with retrovirus for 48 hours, then placed into media containing 5µg/mL puromycin (Gibco) for 
selection of cells successfully incorporating the desired shRNA. Cells surviving puromycin 
selection were split and either frozen or utilized for protein extraction. Bptf KD cell lines were 
confirmed via Western blot analysis off of 6 well plates, and again off of 10 cm plates to ensure 
KD consistency. Cell lines were then frozen down and stored in liquid nitrogen. 
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Creating OVA Cell Lines 
Melanoma (B16F10) cells were plated and co-transfected with DNA for both the 
ovalbumin (ova) and zeocin resistance genes. Ovalbumin DNA received from the Wang lab was 
altered to remove the existing puromycin resistance gene. Cells were transfected with the 
ovalbumin and zeocin resistance DNA and Lipofectamine 2000 (Invitrogen) for 48 hours, then 
placed into media containing 0.2% zeocin (Invitrogen) over multiple weeks for selection of cells 
incorporating the desired segments. Single clones were isolated and screened for incorporation of 
ovalbumin by flow cytometry utilizing staining with OVA257-264 peptide bound to H-2Kb (BD 
Pharmingen) on the BD FACS Calibur Flow Cytometer. Two separate cell lines (out of 15 
screened) incorporating ovalbumin were then utilized to create Bptf KD and control cell lines as 
described above. Both Bptf KD and ovalbumin expression were confirmed by Western blot 
analysis. 
 
Solid Tumor Flow Cytometry 
Spleens from Bptf KD and control tumor-bearing mice and tumors were extracted from 
mice and placed on ice. Tumors were weighed, then mechanically minced by razor blade in a 
petri dish. Tumors were subsequently digested in enzyme solution containing 1µg/mL 
Collagenase Type IV (Sigma) and 20 µg/mL DNase I (Sigma) in PBS (10mL of enzyme solution 
for tumors 1 cm² in size) for 90 minutes in a 37°C water bath. During the 90 minute incubation, 
digests were inverted every 15 minutes. Digests were then filtered through a 40 µm filter and 
centrifuged at 1500 rpm for 5 minutes at room temperature. After removal of the supernatant, 
cells were resuspended in 9 mL 40% Percoll (Sigma) diluted in PBS and carefully layered on top 
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of 4 mL of 70% percoll containing 10 µL 0.5% phenol red dye (Sigma) in PBS, creating a 
discontinuous gradient. Percoll gradients were centrifuged at 3000 x g for 30 minutes at room 
temperature with minimal acceleration and brake. Cells at the interface were collected and 
diluted with 30 mL PBS, then centrifuged at 1500 rpm for 5 minutes. Supernatant was removed, 
and cells were resuspended in 1 mL of cold FACS buffer. Cells were then counted in a 1:1 ratio 
of 0.2% trypan blue viability dye and split evenly into two tubes.  
Spleens, utilized for compensation controls in addition to being samples, were placed on 
a petri dish in 1 mL cold FACS buffer and sliced in half lengthwise with a razor blade. 
Splenocytes were massaged out with the flat end of a sterile 5 mL syringe plunger and filtered 
through a 40 µm filter. Splenocytes were separated into multiple tubes for samples and controls 
and centrifuged at 500 g for 5 minutes at room temperature. Supernatants were removed and 
cells were resuspended in 500 µL RBC lysis buffer (155 mM NHCL, 12 mM NaHCO,  
0.1 mM EDTA in molecular grade water). The RBC lysis reaction continued room temperature 
for 4-5 minutes and was stopped with 1 mL PBS. Splenocytes were centrifuged at 500 g for 5 
minutes and resuspended in 1 mL cold FACS buffer (2% FBS in Hank’s balanced salt solution 
(HBSS)). 
All samples were stained with a combination of CD8 (FITC), TCRβ (PE), or CD69 (PE) 
antibodies (BD Pharmingen) for 20 minutes, shielded from light. Cells were washed twice in 1 
mL cold FACS buffer and resuspended in 500µL FACS buffer containing 2 ng/mL 7AAD 
(Sigma) for analysis by flow cytometer (BD FACS Calibur Flow Cytometer). Flow cytometry 
data was analyzed using FlowJo software. 
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Cell Culture Flow Cytometry 
Cells cultured to approximately 80% confluence were washed twice with 1X PBS and 
placed in 1 mL Cellstripper (Cellgro) solution at 37°C until single cell suspension was reached. 
Cells were then centrifuged at 350 g for 5 minutes, resuspended in 1 mL FACS buffer, and 
stained with OVA(257-264) peptide bound to H-2Kb (eBioscience, 12-5743-81) for 20 minutes, 
shielded from light. Cells were washed twice in 1 mL cold FACS buffer and resuspended in  
500 µL cold FACS buffer for analysis by flow cytometer (BD FACS Calibur Flow Cytometer). 
Flow cytometry data was analyzed with FlowJo software. 
 
ELISA 
eBioscience ELISA Ready-Set-Go! protocol was followed as provided by the company. 
Briefly, 96-well plates were coated with capture antibody and incubated overnight at 4°C. Wells 
were washed with provided Wash Buffer, blocked for 1 hour at room temperature in diluted 
Assay Diluent, and then washed again. Standards and samples were added (100 µL/well) and 
incubated overnight at 4°C. Wells were washed the next morning, placed in primary (detection) 
antibody for 1 hour at room temperature, washed, placed in secondary (Avidin-HRP) antibody 
for 30 minutes at room temperature, and washed again. Finally, 100µL of Substrate Solution was 
added to each well for 15 minutes at room temperature before 50µL Stop Solution was added to 
each well and the plate was read at 450 nm and 570 nm by spectrophotometer (Synergy H1 
Multi-Mode Plate Reader, BioTek). 
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LDH Cytotoxicity Assay 
Promega CytoTox 96 Non-Radioactive Cytotoxicity Assay protocol was followed as 
provided by the company. Briefly, a 96-well plate was plated with 1,000 effector cells/well and 
incubated overnight at 37°C. The following morning, target cells were added to all experimental 
wells and appropriate control wells in pre-determined effector:target ratios, and the plate was 
centrifuged for 4 minutes at 250 g. The plate was then incubated at 37°C overnight, after which 
provided 10X Lysis Solution was added to appropriate. Supernatant (50µL) from each of the 
wells was then transferred to an enzymatic assay plate where 50 µL of Substrate Mix was added 
to each well. The enzymatic assay plate was covered and incubated for 30 minutes at room 
temperature, shielded from light. Finally, after the 30 minute incubation, 50 µL Stop Solution 
was added to each well and the absorbance was read at 490 nm by spectrophotometer (Synergy 
H1 Multi-Mode Plate Reader, BioTek).  
Western Blot 
Cultured cells were washed twice with PBS, then placed in 1 mL of TRI reagent (Sigma) 
and incubated at room temperature for 10 minutes. The 1 mL of TRI reagent was then forcefully 
pipetted over the cells multiple times to homogenize the extract. The sample was placed into a 
1.5 mL centrifuge tube and 200 µL chloroform was added. Samples were vortexed for 15 
seconds, allowed to sit at room temperature for 10-15 minutes, and centrifuged at 12,000 x g at 
4°C for 15 minutes. The upper clear aqueous layer containing RNA and thin viscous interphase 
containing DNA were removed by vacuum and 1 mL isopropanol was added to the organic layer. 
The sample was inverted to mix and incubated at room temperature for 10 minutes while a while 
precipitate (protein) formed. Samples were then centrifuged at 12,000 x g at 4°C for 10 minutes 
and the supernatant was aspirated. To the protein pellet, 1.5 mL of 0.3 M guanidine in 95% 
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ethanol was added. The pellet was dislodged and the sample was placed on a rocker at 4°C 
overnight. The next day, samples were centrifuged at 12,000 x g at 4°C for 15 minutes. After 
aspiration of the supernatant, 1.5 mL 100% ethanol was added and incubated at room 
temperature for 20 minutes. Samples were subsequently vortexed and spun down at 12,000 x g at 
4°C for 15 minutes and the supernatant was aspirated. To the pellet, 200 µL 8M urea in 1% SDS 
was added and samples were incubated at 65°C overnight. The following morning, protein was 
quantified for each sample against standards (0 mg/mL, 0.75 mg/mL, 1.5 mg/mL, and 3 mg/mL 
all in BSA) using BioRad DC Protein Assay reagents, incubated at room temperature for at least 
10 minutes, and absorbance was measured at 750 nm by spectrophotometer (Pharmacia LKB 
Ultrospec III). 5X SDS loading buffer and 8M urea in 1% SDS were added to bring each sample 
to a protein concentration of 2 mg/mL. 
Cell protein extracts (40µg) were then run on a 4%, 6%, 10%, or 15% Tris/Glycine gel 
(depending on protein size) for 1 hour at 200 V and 200 mA. Protein extracts were then 
transferred to Immuno-Blot polyvinylidene difluoride (PVDF) membrane (Bio-Rad) by Western 
blot in either CAPS buffer (10 mM CAPS pH 10.5, 00025% 1 M DTT in diH2O) or 1X 
Tris/Glycine transfer buffer (25 mM Tris, 190 mM Glycine) for 17 hours at 20 V and 20 mA. 
Membranes were removed and blocked in 5% NFDM in PBST (PBS, 0.001% Tween-20) for 1 
hour, then placed in 10 mL 5% NFDM in PBST and primary antibody and incubated on an 
orbital shaker overnight at 4°C. Primary antibody concentrations added were as follows: 3 µL α-
Bptf (Landry), 10 µL α-Ovalbumin (Santa Cruz Biotechnology, 3G2E1D9), or 10 µL Pmel17 
(Santa Cruz Biotechnology, H-300) per membrane. After incubation in primary antibody, 
membranes were rinsed with PBST 3 times for 7 minutes each, and blocked in 10 mL 5% NFDM 
in PBST and secondary antibody for 1 hour. Secondary antibody concentrations added were as 
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follows: 1µL anti-mouse IgG (Cell Signaling Technology, #7076), or 1 µL anti-rabbit IgG (Cell 
Signaling Technology, #7074). Membranes were then rinsed again in PBST 3 times for 7 
minutes each. Membranes were bathed in 500 µL ECL (Thermo Scientific SuperSignal West 
Femto), wrapped in a single layer of cling wrap and placed on x-ray film for varying lengths of 
time. Films were developed using an automated tabletop processor. 
 
Quantitative Western Blot 
Cell protein extracts (40µg) were run on a 6%, 10%, or 15% Tris-Glycine gel for 1 hour 
at 200 V and 200 mA. Protein extracts were then transferred to Immuno-Blot PVDF membrane 
(Bio-Rad) by Western blot in CAPS buffer or Tris/Glycine transfer buffer for 17 hours at  
20 V and 20 mA. Membranes were removed and blocked in 5% NDFM in PBST for 1 hour, then 
placed in 10 mL 5% NFDM in PBST and primary antibody and incubated on an orbital shaker 
overnight at 4°C. Primary antibody concentrations added were as follows: 3 µL α-Bptf (Landry), 
10 µL α-Ovalbumin (Santa Cruz Biotechnology, 3G2E1D9), 10 µL Pmel17 (Santa Cruz 
Biotechnology, H-300), or 1 µL cyclophilin B (abcam, ab3565) per membrane. After incubation 
in primary antibody, membranes were rinsed with PBST 3 times for 7 minutes each, and blocked 
in 10 mL 5% NFDM in PBST and secondary antibody for 1 hour. Secondary antibody 
concentrations added were as follows: 1 µL anti-mouse IgG (Cell Signaling Technology, #7076), 
or 1 µL anti-rabbit IgG (Cell Signaling Technology, #7074). Membranes were bathed in 500 µL 
ECL (Thermo Scientific SuperSignal West Femto) and placed on the provided tray and inserted 
into the Odyssey Fc (LI-COR) imaging system for quantitative image capture and analysis.
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RESULTS 
 
Bptf KD Tumors Display an Elevated CD8 T Cell Population 
It was previously observed through systematic depletion of immune cells that CD8 cells 
are an essential part of the mechanism involved in the phenotypic difference seen between 
control and Bptf KD tumors. Prior experiments also revealed that CD8 T cells primed on Bptf 
KD cells kill Bptf KD cells more effectively than T cell primed on control cells kill control cells 
in vitro. To determine whether the mechanism behind the increased cytotoxicity of Bptf KD T 
cells was due to an increase in activated CD8 T cells in Bptf KD tumors, flow cytometry was 
performed on Bptf KD and control solid tumors obtained the same day.  
The presence of tumor infiltrating CD8 cells was evaluated by staining cells for both CD8 
and TCRb in both 4T1 and B16F10 control and Bptf KD tumors. A stepwise gating strategy 
(Figure 10). First, the lymphocyte population was isolated, then gating specifically on live cells, 
and finally gating on the CD8 positive population within the TCRb population was employed. 
Percentages, as opposed to cell counts, were utilized to account for the difference in tumor 
weight as well as variability in cell counts between samples of the same tumor, and to enable 
direct comparisons between tumors.  
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Figure 10: Gating Strategy for Determining CD8 Populations. (A) Gating strategy utilized in 
tumors. The lymphocytes population was first gated off of, followed by the live population of 
lymphocytes. TCRb+ cells were then gated out of the live population, and of that population, 
CD8+ (double positive for TCRb and CD8) T cells were determined. (B) The same gating 
strategy as described in A shown for spleens. 
 
The T cell population was considered to be all cells staining positive for TCRβ, after 
isolation of live lymphocytes. Exact gating strategies employed for extraction of the CD8 cell 
population in tumors and spleens are illustrated in Figure 10. 
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Figure 11: CD8+ T Cell Population in 4T1 and B16F10 Tumors. Dot plots showing 
TCRb+/CD8+ cells in a single tumor for control and Bptf KDs in 4T1 (A) and B16F10 (B) 
tumors.   
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Figure 12:  CD8+ T Cell Population in Tumors and Spleens. Representative Bptf KD (red) 
and control (black) CD8+ populations by tumor weight showing a significant difference between 
Bptf KD and control tumor CD8+ populations in 4T1 (A) and B16F10 (B) tumors. Similar 
analysis of CD8+ populations in spleens by tumor weight in both 4T1 (C) and B16F10 (D) mice 
showing no significant difference. 
 
Dot plots for the percentage of CD8+ T cells in single 4T1 and B16F10 control, Bptf KD 
1, and Bptf KD 2 tumors are provided in Figure 11. Analysis of the microenvironment of 
multiple tumors derived from both the 4T1 and B16F10 cell lines showed significant differences 
in CD8+ T cell populations between control to Bptf KD tumors. There were significantly more 
CD8+ T cells in Bptf KD tumors as compared to control tumors for both 4T1 (p-value = 0.03) 
and B16F10 (p-value = 0.05), as shown in Figure 12. Trends between CD8+ T cell levels and 
tumor weights were also visualized. As tumor weight decreased, the presence of CD8+ cells 
increased in both 4T1 (Figure 12A) and B16F10 tumors (Figure 12B). In splenocytes from 4T1 
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and B16F10 tumor-bearing mice, however, the opposite trend was shown in all but one 
population. For spleens from 4T1 control, Bptf KD (Figure 12C), and B16F10 control tumor-
bearing mice (Figure 12D), as tumor weight increased, the percentage of CD8+ splenocytes also 
increased. Conversely, in splenocytes from B16F10 Bptf KD tumor-bearing mice, it was seen 
that the CD8+ population decreases with increasing tumor weight (Figure 12D). 
 
Figure 13: Gating Strategy for Determining Active CD8 Populations. (A) Gating strategy 
utilized in tumors. The lymphocytes population was first gated off of, followed by the live 
population of lymphocytes. CD8+ cells were then gated out of the live population, and of that 
population, CD69+ (double positive for CD8 and CD69) T cells were determined. (B) The same 
gating strategy as described in A shown for spleens. 
 
Tumors derived from 4T1 and B16F10 cell lines were also analyzed for CD8 T cell 
activation status. Exact gating strategies employed for determination of the active CD8 
population in tumors and spleens are illustrated in Figure 13. Dot plots for active (CD69+) CD8+ 
T cell determination in single 4T1 and B16F10 control, Bptf KD 1, and Bptf KD 2 tumors are 
provided in Figure 14. While significant differences in active CD8+ T cell populations were not 
observed between control to Bptf KD tumors, a clear trend was again visualized. As tumor 
weight decreased, the presence of active CD8+ cells in the tumor microenvironment increased in 
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4T1 Bptf KD and control tumors (Figure 15A), as well as B16F10 Bptf KD tumors (Figure 15B). 
The microenvironment of B16F10 control tumors showed an opposing correlation, with active 
CD8 cell status increasing with increasing tumor weight (Figure 15B). Analysis was also 
performed on the spleens of 4T1 and B16F10 Bptf KD and control tumor-bearing mice. No 
significant differences were observed between control and Bptf KD groups, however a similar 
trend was detected. In splenocytes from 4T1 Bptf KD or control tumor-bearing mice (Figure 
15C) or B16F10 control tumor-bearing mice (Figure15D), activation status of CD8 cells 
decreased as tumor weight increased. The activation status of CD8 cells in splenocytes from 
B16F10 Bptf KD tumor-bearing mice did not follow this trend as definitively as other groups 
(Figure 15D). 
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Figure 14: Active CD8 T Cell Population in 4T1 and B16F10 Tumors. Dot plots showing 
CD8+/CD69+ cells in a single tumor for control and Bptf KDs in 4T1 (A) and B16F10 (B) 
tumors. 
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Figure 15: Active CD8 Population Decreases with Increasing Tumor Weight.  
(A) Representative Bptf KD (red) and control (black) CD69+ populations by tumor weight 
illustrating the trend that as tumor weight decreases, presence of CD69+ CD8 T cells increases in 
Bptf KD and control 4T1 tumors. (B) Similar analysis of B16F10 Bptf KD and control tumors. 
Similar analysis of CD8+ populations in spleens by tumor weight in both 4T1 (C) and B16F10 
(D) mice showing a decrease in CD69+ population as tumor size increases. 
 
Bptf KD Tumors do not Present OVA or Pmel-17 Antigen with Greater Efficiency 
 Previous data gathered or provided evidence for the upregulation of genes involved in 
MHC Class I antigen processing. Additional experimental data went on to illustrate no 
significant increase in the overall presence of MHC Class I molecules on the cell surface. With 
this information, we set out to determine if Bptf KD cells alter antigen presentation. Specifically, 
we wanted to extrapolate whether antigen is presented with greater efficiency on the surface of 
Bptf KD tumor cells as compared to control tumor cells.To determine if Bptf KD tumors present 
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antigen in greater amounts on the cell surface, two separate model systems utilizing known 
antigen were evaluated.  
OT1 Model 
The OT-1 model is well characterized and frequently used for investigation into antigen 
presentation and CD8 T cell responses to antigen [53,54,55,56]. OT-1 mice are C57BL/6 mice 
transgenic for the OT-1 T-cell receptor, producing CD8 T cells that are MHC class I restricted 
and ovalbumin (257-264) specific [57]. OVA, the gene encoding for the hen egg protein 
ovalbumin, is not native to the B16F10 cell line. With previous data showing KD of Bptf results 
in dysregulation of MHC Class I associated genes, dysregulation of genes associated with 
antigen processing for MHC Class I molecules, and the importance of CD8+ T cells in the 
mechanism used in Bptf KD tumors, use of the OT-1 model (with a known non-native antigen 
specific for MHC Class I that utilizes restricted CD8+ T cells) was chosen. Once incorporated 
into the desired cell line(s), presentation of OVA (257-264) in the context of MHC Class I 
haplotype H2-Kb can be evaluated to determine antigen presentation efficiency and CD8 T cell 
cytotoxicity.  
The ovalbumin (OVA) gene was introduced into B16F10 cells to create the parents cell 
lines used for this model. Flow cytometry of the lines was utilized to confirm expression of OVA 
on the cell surface (Figure 16).  
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Figure 16: Confirmation of Ovalbumin Gene Incorporation and Expression in B16F10 Cell 
Lines. Expression of OVA(257-264) complexed with H2-Kb on B16F10 cells. Isotype (gray), 
B16F10 control without OVA (black), two B16F10 lines transfected with OVA (red).  
 
 Bptf KD lines were created from the B16F10 clones incorporating the OVA gene, and 
expression of both OVA and Bptf were confirmed via Western blot (Figure 17A). Cell lines were 
then evaluated for OVA expression by quantitative Western blot and flow cytometry. For 
quantitative western blot data analysis, OVA expression was determined as the ratio of OVA 
expression to that of cyclophilin B as loading control for each sample. Analysis revealed no 
significant difference in OVA expression from control to Bptf KD lines (Figure 17B).  
 OVA expression of Bptf control and KD cell lines was also evaluated by flow cytometry. 
The OVA antibody used for flow cytometry analysis was for OVA(257-264) peptide complexed 
with the H2-Kb molecule. Analysis of both MHC Class I molecule H2-Kb and OVA expression 
revealed a slight increase in H2-Kb expression in Bptf KD cell lines, but no discernable 
difference in cell surface OVA expression levels (Figure 17D). Analysis of H2-Kb alone ensured 
any observed change in OVA expression localized to the cell surface was not due to an increase 
in cell surface MHC Class I H2-Kb. Mean fluorescence intensity (MFI) of both H2-Kb and OVA 
were also calculated from flow cytometry data. OVA expression for control and Bptf KD cell 
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lines was calculated as a ratio of OVA MFI to H2-Kb MFI. This analysis revealed a visible but 
insignificant decrease of cell surface OVA expression in Bptf KD cells (Figure 17C). 
 
Figure 17: Relative OVA Expression of Bptf Control and KD Cell Lines as Determined by 
Flow Cytometry Analysis. (A) Western blot analysis confirming ova expression in OVA cell 
lines and not control. Bptf KD was also confirmed, with B16F10+OVA lines with Bptf KD 
showing no expression of Bptf compared to controls. Ponceau staining provided as loading 
control. (B) Quantitative Western blot analysis of OVA expression shown as a ratio of OVA 
expression to the loading control cyclophilin B. (C) MFI of OVA expression as a ratio of OVA 
to H2-Kb in control and Bptf KD B16F10+ova cells, determined by flow cytometry. (D) Flow 
cytometry of H2-Kb and OVA expression in B16F10+ova Bptf KD and control cell lines. 
Isotype (gray), B16F10+OVA control (black), B16F10:OVA Bptf KDs (red and green).  
35 
 
 T cells obtained from an OT-1 mouse were then placed onto B16F10+OVA control and 
Bptf KD cell lines to determine cell death in vitro. A preliminary LDH cytotoxicity assay 
performed revealed no significant difference in cell death from B16F10+OVA control to Bptf 
KD cell lines (Figure 18). 
  
Figure 18: LDH Cytotoxicity of Bptf Control and KD OVA-Expressing T Cells. No 
significant difference was revealed between control and Bptf KD B16F10+OVA cells 
concerning cell death efficiency as determined by preliminary LDH cytotoxicity assay.  
 
Pmel-17 Model 
 A second model used focused on presentation of a known native antigen, as opposed to 
the non-native antigen introduced through the OT-1 model. The Pmel-17 model focuses on the 
presentation of the naturally expressed Pmel-17 antigen in C57BL/6 mice. Pmel-17 is a naturally 
expressed antigen found on both normal melanocytes, as well as a large portion of malignant 
melanomas in humans [58,59]. Analysis of the expression of pmel-17 on B16F10 control and 
Bptf KD cell lines will allow examination of antigen presentation efficiency and cytotoxicity in 
the same manner as the OT-1 model, but provide insight into the antigen presentation status of 
native antigens. 
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 Expression of Pmel-17 and Bptf were confirmed in existing control and Bptf KD B16F10 
cell lines by Western blot (Figure 19). These cell lines were then evaluated for expression of 
Pmel-17 by Western blot analysis (Figure 19).  
 
Figure 19: Stable Bptf KD and Pmel-17 Expression of B16F10 Cell Lines. Western blot 
analysis confirming expression of Pmel-17 and appropriate levels of Bptf in control and Bptf KD 
B16F10 cells. Ponceau staining provided as loading control.  
 
 T cells obtained from a Pmel-17 mouse were then placed onto B16F10 control and Bptf 
KD cell lines to determine cytotoxicity and cell death in vitro. Preliminary LDH cytotoxicity 
assays revealed a decrease in cytotoxic effect of T cells to Bptf KD tumor cell targets as 
compared to control tumor cell targets (Figure 20A). Preliminary analysis of cell death by 
ELISA was also performed, showing evidence in concurrence with LDH cytotoxicity assay 
results. Figure 20B illustrates the decrease in IFN-γ release induced by Pmel-17 T cells placed on 
Bptf KD tumor cell targets as compared to Pmel-17 T cells placed on control tumor cell targets 
seen through IFN-γ ELISA analysis. 
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Figure 20: LDH Cytotoxicity of Pmel-17 T Cells Similar on Bptf Control and KD Cell 
Lines. Preliminary LDH cytotoxicity assay (A) and IFN-γ ELISA (B) results showing a decrease 
in cell death of Bptf KD cells by Pmel-17 sensitive CD8+ T cells. 
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DISCUSSION 
 
While advances in cancer treatment have been made over the past 25 years, 1 in 4 deaths 
in the United States continues to be attributed to cancer [1].  Of the treatments available, 
immunotherapies are relatively recent and have gained notoriety with their ability to mitigate 
diseases that previously had a grim outlook and little to no available therapy, including cancer. 
Even with great strides being made in immunotherapies, epigenetics is an avenue of 
immunotherapy yet to be fully exploited for its therapeutic possibilities. 
  Through studies of the Bptf subunit, the chromatin remodeler NURF presents itself as a 
potential therapeutic target, with prior research demonstrating its necessity for embryonic 
development through Bptf KO cells, but also showing Bptf is not cell essential through use of 
cell-type specific Bptf KO studies [15,16]. Previous data revealing a decrease in tumor weights 
when Bptf is knocked-down heighten its therapeutic possibilities. With data indicating Bptf acts 
through manipulation of the immune system, Bptf begins to present itself as a target for future 
immunotherapies.  
While Bptf is a likely candidate for immunotherapies, further investigation into the 
particular mechanism by which Bptf acts on the immune system will present even greater 
therapeutic possibilities.   Once a mechanism is elucidated, manipulation of multiple portions of 
said mechanism could provide a variety of different clinically relevant areas of attack in the 
battle against cancer.  
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To begin to illuminate the mechanism by which Bptf decreases tumor weight, we 
examined the microenvironment of the tumor itself utilizing flow cytometry of two separate cell 
lines: 4T1 and B16F10.  After digestion of the tumor and isolation of lymphocytes, cells were 
stained with a combination of antibodies for TCRβ, CD8, CD69. From a combination of these 
stains, we were able to determine the percentage of live CD8 cells present in the tumor 
microenvironment, as well as the percentage of live active CD8 cells present.  
A total of 6 representative 4T1 tumors (3 control and 3 Bptf KD) and 6 melanomas (3 
control and 3 Bptf KD) derived from the B16F10 cell line in addition to spleens from tumor-
bearing mice were obtained and analyzed by flow cytometry for this project. In 4T1 and B16F10, 
we observed a significant increase in the percentage of CD8+ T cells in Bptf KD tumors as 
compared to controls. While no significant differences were realized in other relationships, 
multiple trends developed, including that of an increase in active CD8 T cells as tumor weight 
decreased.  These insignificant differences may be realized as significant with additional data 
collection and analysis, due to time restrictions associated with this project.  
From currently available data, there is an elevation of CD8+ T cells in the Bptf KD tumor 
microenvironment of both 4T1 and B16F10 cell line origin as compared to control. At this time, 
it is likely beneficial to reserve judgement on data obtained from B16F10 tumors, as they did not 
provide consistent results and analysis was based on a low number of available T cells. B16F10 
tumors are known to harbor fewer T cells than other cancer cell lines [60]. This could not only 
make the recovery of T cells more difficult, but could contribute to any insignificance of data 
gathered, as greater cell counts contribute to more consistent and more reliable data analysis. 
With further adjustments made on the protocol utilized to obtain lymphocytes, including 
compilation of multiple control or Bptf KD tumors into one sample, elevated and consistent T 
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cell counts could be obtained. Once consistent results are obtained, more weight would be given 
to B16F10 data. At this time, a higher level of confidence is had in the data obtained from 4T1 
tumors, which provided a more reasonable number of T cells for analysis.  
CD8+ cells are activated once they recognize and come in contact with the antigen:MHC 
Class I complex on a cell [28]. In the immunological environment of a tumor, CD8+ cells can be 
presented with novel antigens or native antigens. Analysis of CD8 T cell activation status in the 
tumor microenvironment by flow cytometry showed that as tumor weight decreased, active CD8 
T cell population increased. To explain a more active CD8+ T cell phenotype seen in Bptf KD 
tumors, CD8+ cells are likely either presented with novel antigens from the tumor, or tumors are 
exhibiting increased presentation of native antigens. Novel antigen presentation could attract 
more attention from the immune system and increase the activation of CD8+ cells, likely 
increasing cell death and providing definitive therapeutic potential. An increase in the efficiency 
of antigen presentation would provide more opportunities for recognition by cytotoxic CD8+ 
cells and therefore an increased chance of tumor cell death by CD8 cytotoxicity mechanisms, but 
provide a less clear-cut therapeutic opportunity. 
While ongoing studies in the Landry Lab are investigating the possibility that Bptf KD 
tumor cells display novel antigens, the studies contained in this project explore the concept of 
increased antigen presentation occurring on Bptf KD tumor cells. Two separate models with 
known antigens were utilized for analysis of antigen presentation efficiency.  
After we incorporated the ovalbumin gene into B16F10 cell lines for use of the OT-1 
model, and subsequently introduced control or Bptf KD shRNA, we began analyses. OVA 
expression was consistently shown to have no significant difference in expression from control 
to Bptf KD cell lines. With no significant difference in presentation of the OVA antigen on the 
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cell surface, it was anticipated that no difference in cell death would be seen between OVA-
expressing control and Bptf KD cells when exposed to CD8+ cells restricted to OVA. For use of 
the Pmel-17 model, CD8+ T cells were purified from the spleen of a Pmel-17 mouse and assays 
investigating cell death began. Cell death was measured through LDH cytotoxicity assay and/or 
IFN-γ ELISA.  Only preliminary data for both the OT-1 and Pmel-17 models was obtained for 
this project. Initial data obtained by LDH cytotoxicity assay for the OT-1 model showed no 
significant difference between B16F10+OVA control and Bptf KD cell lines. Preliminary LDH 
cytotoxicity assay data for Pmel-17 showed a decrease in Bptf KD cell death when exposed to T 
cells from a Pmel-17 mouse as compared to controls. Preliminary IFN-γ ELISA data for Pmel-17 
showed a decrease in IFN-γ production in wells containing Pmel-17 CD8 T cells placed on Bptf 
KD tumor cells as compared to wells with T cells placed on control tumor cells. 
From data gathered during this project, the possible mechanisms behind decreased tumor 
weights in Bptf KD tumors begin to be narrowed down. IFN-γ and LDH cytotoxicity assays of 
both the OT-1 and Pmel-17 models, in combination with flow cytometry and quantitative 
Western blot analysis, reveal Bptf KD cells are likely not presenting antigen more efficiently on 
tumor cell membranes. These results support the model of a novel or tumor-associated antigen 
being presented on the surface of tumor cells. Flow cytometry of control and Bptf KD tumor 
microenvironments revealed Bptf KD tumors have an increased presence of CD8+ T cells that 
likely have an increased activation status as compared to controls. While much additional 
information must be gathered before making definitive conclusions, it is possible that Bptf KD 
tumor cells are presenting an antigen not normally expressed on that cell type/stage, resulting in 
an increase CD8+ and active CD8+ cell presence and increased tumor cell death by direct CD8 
cytotoxicity mechanisms. These direct cytotoxicity mechanism could include release of perforin 
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and granzyme, release of IFN-γ and subsequent induction of the JAK/STAT pathway, or 
induction of the Fas/TRAIL pathway.  
As stated previously, there are multiple limitations of this study. When use of tumors 
obtained the same day is required in any experiment, troubleshooting can be a significant source 
of delay, as we must have mice readily available for injection of cells that will take weeks to 
form tumors. If additional control and Bptf KD tumors are able to be gathered and analyzed, 
more distinct trends may be elicited. In regards to flow cytometry analysis of T cells obtained 
from B16F10 tumors, the minimal recovery of T cells may hinder the consistency of data 
obtained, requiring additional replicates to be completed for accurate results. Due to time 
restraints, all LDH cytotoxicity assay and ELISA data is to be considered preliminary, with 
replicates to be completed in the future for confirmation of results. 
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